|
Synonyms: KH902 | KH903 | Lumitin® (China)
conbercept is an approved drug
Compound class:
Peptide
Comment: Conbercept is a VEGF ligand trap. It comprises VEGF binding domains from VEGF receptors 1 and 2 including VEGFR-2 domain 4, fused to a human IgG Fc domain. Conbercept binds to and neutralizes all VEGF isoforms [4].
|
| References |
|
1. Liu B, Qiao Q, Dang Y. (2026)
Efficacy and safety of ranibizumab, aflibercept, and conbercept in the treatment of diabetic macular edema: a retrospective comparative study. Sci Rep, 16 (1). [PMID:41927686] |
|
2. Liu K, Wang H, He W, Ye J, Song Y, Wang Y, Liu X, Wu Z, Chen S, Fan K et al.. (2022)
Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study. Br J Ophthalmol, 106 (10): 1436-1443. [PMID:34001667] |
|
3. Shalchi Z, Mahroo O, Bunce C, Mitry D. (2020)
Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion. Cochrane Database Syst Rev, 7 (7): CD009510. [PMID:32633861] |
|
4. Zhang M, Zhang J, Yan M, Li H, Yang C, Yu D. (2008)
Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choridal neovasularization in monkeys. Mol Vis, 14: 37-49. [PMID:18246030] |